SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis

Table 8 Multivariate analysis of factors influencing disease-free survival in 402 patients with gastrointestinal stromal tumor

Factor		Model A		Model B		Model C
		DFS HR(95%CI)	P value	DFS HR(95%CI)	P value	DFS HR(95%CI)	P value
Primary tumor site	Gastric: Non-gastric	1.762 (1.036-2.999)	0.0371	2.046 (1.232-3.401)	0.0062	1.593 (0.928-2.733)	0.091
Primary tumor size (cm)	≤ 5: > 5	1.388 (0.567-3.398)	0.473	3.370 (1.545-7.351)	0.0022	1.183 (0.477-2.934)	0.717
Mitotic index (HPFs)	≤ 5/50: 6-10/50: > 10/50	2.027 (1.494-2.749)	< 0.0012	2.549 (1.930-3.366)	< 0.0012	2.032 (1.496-2.760)	< 0.0012
NIH stage	Very low: Low: Mid: High	2.753 (1.426-5.314)	0.0032			2.707 (1.387-5.283)	0.0042
SLITRK3 expression	(-): (+): (++): (+++)			1.508 (1.151-1.976)	0.0032	1.465 (1.114-1.928)	0.0062

¹Statistically significant (P < 0.05);

²Statistically significant (P < 0.01). Model A includes analysis of NIH stage without SLITRK3; model B includes SLITRK3 without NIH stage; model C includes both of them. Mid = intermediate.